Services do NOT include

Please contact the service provider to discuss your study outline.

Possible Output

Summary of results.

Sample Requirements - input of users

Various. To be discussed before starting.

Lead Scientist

Dr. Thomas Courant

Adjuvant and formulation services


Description of service

Users can ship their Sars-Cov2 vaccine antigens to the Vaccine Formulation Institute (VFI) for formulation with VFI adjuvants. Among these adjuvants, a squalene oil-in-water emulsion and a liposome-based formulation containing QS21 are on track to be available at clinical-grade in the context of the development of vaccines against Covid-19. Users can also request a specific adjuvant to be included in the formulation studies.

Once optimal formulations are identified (including physico-chemical characteristics of the adjuvanted vaccine candidate), VFI can perform immunogenicity studies in mice including analyses of B- and T-cell responses. 

A brief report of the study results will be provided to the User.


Project duration approximately 2 months


Dr. Maria Lawrenz 


This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.

Be the first to know about the upcoming application calls, follow European Vaccine Initiative on:

  • LinkedIn Social Icon
  • Twitter Social Icon

Designed by European Vaccine Initiative